Company & Sponsor Intelligence
Janssen Research & Development, LLC
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials16
Recruiting0
Completed12
Countries4
Therapeutic footprint
alzheimersautismdepressionschizophrenia
Indexed studies
NCT02197884A Study to Assess Effects of Clarithromycin on Pharmacokinetics of JNJ-54861911 in Healthy Male Participants
alzheimers · BelgiumPHASE1
alzheimers · BelgiumPHASE1
NCT02114372Cognitive Health in Ageing Register: Investigational, Observational and Trial Studies in Dementia Research: Prospective Readiness Cohort Study
alzheimers · United KingdomCOMPLETED
alzheimers · United KingdomCOMPLETED
NCT02902601A Study to Investigate the Safety, Tolerability, and Pharmacodynamics of JNJ-54175446 in Participants With Major Depressive Disorder
depression · GermanyPHASE1
depression · GermanyPHASE1
NCT03375697A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Subjects and Subjects With Alzheimer's Disease
alzheimers · BelgiumPHASE1
alzheimers · BelgiumPHASE1
NCT05841030A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)
depression · United StatesCOMPLETED
depression · United StatesCOMPLETED
NCT01128452Safety and Efficacy of EVT 101 in Treatment-Resistant Depression
depression · United StatesPHASE2
depression · United StatesPHASE2
NCT02462473A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry
schizophrenia · United StatesPHASE2
schizophrenia · United StatesPHASE2
NCT04619420A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease
alzheimers · United StatesPHASE2
alzheimers · United StatesPHASE2
NCT04533529A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant
depression · United StatesPHASE3
depression · United StatesPHASE3
NCT04532749A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
depression · United StatesPHASE3
depression · United StatesPHASE3
NCT04571697A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy
alzheimers · United StatesCOMPLETED
alzheimers · United StatesCOMPLETED
NCT01978548A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease
alzheimers · BelgiumPHASE1
alzheimers · BelgiumPHASE1
Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →